New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
12:13 EDTHNZ, NCT, APKT, EXAS, DELL, ZIOPOptions with increasing implied volatility: ZIOP EXAS NCT DELL APKT HNZ
News For ZIOP;EXAS;NCT;DELL;APKT;HNZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
09:26 EDTZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
June 26, 2015
13:46 EDTEXASFly Watch: Exact Sciences predicted to jump if task force update favorable
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015. The guidelines should include an assessment of Exact Sciences' (EXAS) Cologuard, an "easy to use, noninvasive colon cancer screening test." ANALYST TAKE: The USPSTF guidelines were noted as "the last binary event for Cologuard" by Jefferies and "the major overhang" for Exact Sciences by Mizuho Securities. Jefferies analyst Brandon Couillard and his team, which rate Exact Sciences a Buy with a $33 price target, see "significant upside" from a favorable outcome and said their thesis was boosted by confident comments from a "former affiliate of the USPSTF's review board." Mizuho analysts Peter Lawson and Eric Criscuolo, who rate Exact Sciences a Buy with a $35 price target, said they believe Cologuard will receive an "A" or "B" rating from the USPSTF, triggering further adoption by mandating coverage of Cologuard by private insurance. Baird defended Exact Sciences after the stock dropped 5.5% on Thursday, June 25, saying Exact Sciences' investor relations day was "bullish" in tone as the company provided a "deep dive" update on its Cologuard launch. Baird maintained its Outperform rating and $44 price target on the company. PRICE ACTION: Over the past week, shares of Exact Sciences are up more than 5% despite Thursday's 5.5% pullback. Over the last month, shares are up about 12% and over the last three months they are higher by almost 40%.
08:18 EDTEXASExact Sciences recent weakness unwarranted, says Baird
Subscribe for More Information
07:17 EDTEXASExact Sciences compelling as a platform growth company, says Canaccord
Subscribe for More Information
June 25, 2015
08:03 EDTEXASExact Sciences to host analyst and investor day with a conference call hookup
Subscribe for More Information
07:17 EDTDELLRed Hat to hold a summit
Subscribe for More Information
06:34 EDTEXASExact Sciences' Cologuard shows strong sales in Q2
Subscribe for More Information
June 23, 2015
07:41 EDTDELLRed Hat to hold a summit
Red Hat Summit 2015 is being held in Boston on June 23-26 with webcasted company presentations to begin on June 23 at 4 pm; not all presentations may be webcasted. Webcast Link
June 22, 2015
10:00 EDTZIOPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTHNZFirms fight News Corp in contingent-fee suit, Bloomberg reports
Companies such as HJ Heinz (HNZ) and Henkel (HENKY) subsidiary Dial are among the plaintiffs in a class action lawsuit against News Corp (NWS) that claims its advertising unit has monopolized the market for in-store design services, Bloomberg reports. The companies sued in 2013 originally, and the case was granted class action status last Thursday, the report says. Reference Link
07:59 EDTZIOPZiopharm downgraded on valuation, competition at BMO Capital
As noted earlier, BMO Capital downgraded Ziopharm Market Perform from Outperform. As reasons for the downgrade, the firm cited valuation, increased competition, and its belief that the company has fallen further behind its competitors. Target to $10 from $15.
07:53 EDTEXASExact Sciences estimates raised ahead of analyst Day at Canaccord
Canaccord raised its estimates on Exact Sciences ahead of June 26 Analyst Day. The firm cited the impact from the 160-person sales force addition from Ironwood Pharmaceuticals and pipeline opportunities beyond Cologuard for the increase. Canaccord raised its price target to $32 from $30 on Exact Sciences shares.
06:29 EDTZIOPZiopharm downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use